^
CANCER:

Malignant Pleural Mesothelioma

Related cancers:
No biomarker
Malignant Pleural Mesothelioma
nivolumab + ipilimumab
Sensitive: A1 - Approval
No biomarker
Malignant Pleural Mesothelioma
pemetrexed
Sensitive: A1 - Approval
No biomarker
Malignant Pleural Mesothelioma
carboplatin + pemetrexed
Sensitive: A2 - Guideline
No biomarker
Malignant Pleural Mesothelioma
nivolumab
Sensitive: A2 - Guideline
No biomarker
Malignant Pleural Mesothelioma
bevacizumab
Sensitive: A2 - Guideline
No biomarker
Malignant Pleural Mesothelioma
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Malignant Pleural Mesothelioma
cisplatin + pemetrexed
Sensitive: A2 - Guideline
No biomarker
Malignant Pleural Mesothelioma
carboplatin + raltitrexed
Sensitive: A2 - Guideline
No biomarker
Malignant Pleural Mesothelioma
GC
Sensitive: A2 - Guideline
No biomarker
Malignant Pleural Mesothelioma
gemcitabine
Sensitive: A2 - Guideline
No biomarker
Malignant Pleural Mesothelioma
vinorelbine tartrate
Sensitive: A2 - Guideline
PD-L1 expression
Malignant Pleural Mesothelioma
nivolumab
Sensitive: C3 – Early Trials
WT1 expression
Malignant Pleural Mesothelioma
nivolumab + galinpepimut-S
Sensitive: C3 – Early Trials
TMB-L
Malignant Pleural Mesothelioma
PD1 inhibitor
Resistant: C3 – Early Trials
TMB-L
Malignant Pleural Mesothelioma
PD-L1 inhibitor
Resistant: C3 – Early Trials
PD-L1 underexpression
Malignant Pleural Mesothelioma
PD1 inhibitor
Resistant: C3 – Early Trials
ERCC1 expression
Malignant Pleural Mesothelioma
GC
Sensitive: C3 – Early Trials
RRM1 expression
Malignant Pleural Mesothelioma
GC
Sensitive: C3 – Early Trials
MSLN overexpression
Malignant Pleural Mesothelioma
TC-210
Sensitive: C3 – Early Trials
ASS1 mutation
Malignant Pleural Mesothelioma
cisplatin + pemetrexed + pegargiminase
Sensitive: C3 – Early Trials
PD-L1 overexpression
Malignant Pleural Mesothelioma
nivolumab
Sensitive: C4 – Case Studies
EML4-ALK I1171N + L1196M
Malignant Pleural Mesothelioma
alectinib
Resistant: C4 – Case Studies